89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH by Seini Moimoi | Aug 8, 2019 | Portfolio News
Tricida Announces Second Quarter 2019 Financial Results by Seini Moimoi | Aug 8, 2019 | Portfolio News
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights by Seini Moimoi | Aug 8, 2019 | Portfolio News
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial by Seini Moimoi | Aug 8, 2019 | Portfolio News
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights by Seini Moimoi | Aug 8, 2019 | Portfolio News
